Fig. 4From: LZTS2 promoter hypermethylation: a potential biomarker for the diagnosis and prognosis of laryngeal squamous cell carcinomaKaplan-Meier curves of overall survival in LZTS2 promoter hypomethylated and hypermethylated LSCC patients. Log-rank test results indicated that LSCC patients with LZTS2 hypermethylated promoters (n = 37) had significantly worse overall survival rates than those who had LZTS2 hypomethylated promoters (n = 59) (P = 0.028)Back to article page